pancreatic ductal adenocarcinoma

[Novocure, GmbH] Novocure announced that it has entered into a clinical trial collaboration agreement with Roche, to develop Tumor Treating Fields together with Roche’s anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma.

[Scientific Reports] Using quantitative real-time RT-PCR and western blot analysis, scientists analysed the changes in the expression of HA-synthesizing enzymesand hyaluronan HA-degrading enzymes in pancreatic ductal adenocarcinoma cell lines under hypoxic conditions.

[JCI Insight] Scientists demonstrated that collagen-induced DDR1 activation in cancer cells was a major stimulus for CXCL5 production, resulting in the recruitment of tumor-associated neutrophils, the formation of neutrophil extracellular traps, and subsequent cancer cell invasion and metastasis.

[International Journal of Radiation Oncology Biology Physics] In a panel of 3D, extracellular matrix based PDAC cell cultures, β1 integrin was inhibited by antibodies or siRNA-mediated knockdown. Together with X-ray irradiation and specific chemotherapies, scientists determined 3D colony formation capacity in therapy-naïve and radioresistant PDAC cultures.

[ACS Nano] Investigators developed a size switchable nanosystem based on PEG–PLGA nanospheres encapsulated within liposomes for the combined delivery of vactosertib, a TGF-β1 receptor kinase inhibitor, and the cytotoxic drug paclitaxel.

[Cancer Letters] Scientists discuss the main cellular and molecular mechanisms underlying the involvement of the extracellular matrix, immune cells, and metabolic remodeling in the induction of gemcitabine resistance.